Cytosorbents (CTSO) Invested Capital (2010 - 2026)

Cytosorbents (CTSO) has 17 years of Invested Capital data on file, last reported at $8.8 million in Q1 2026.

• For the quarter ending Q1 2026, Invested Capital fell 39.22% year-over-year to $8.8 million; the trailing twelve-month figure through Mar 2026 stood at $8.8 million (down 39.22% YoY), and the FY2025 full-year result was $5.9 million, down 46.85% from the prior year.
• Invested Capital for Q1 2026 stood at $8.8 million, up from $5.9 million in the prior quarter.
• Across five years, Invested Capital topped out at $55.4 million in Q1 2022 and bottomed at $5.9 million in Q4 2025.
• The 5-year median for Invested Capital is $23.8 million (2023), against an average of $24.9 million.
• The widest annual swing landed in 2024, when Invested Capital slumped 61.06%; it then jumped 79.48% in 2025.
• A 5-year view of Invested Capital shows it stood at $35.4 million in 2022, then dropped by 19.37% to $28.5 million in 2023, then slumped by 61.06% to $11.1 million in 2024, then tumbled by 46.85% to $5.9 million in 2025, then jumped by 49.75% to $8.8 million in 2026.
• The last three Invested Capital figures came in at $8.8 million (Q1 2026), $5.9 million (Q4 2025), and $24.0 million (Q3 2025), per Business Quant data.

Peer Comparison